Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Percheron Therapeutics

    MCap

    AUD8m

    Last close

    AUD0.01

    ▲ 0.00 (25.00%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    LM PAY

    MCap

    EUR24m

    Last close

    EUR37.60

    ▲ 4.00 (11.90%)

  • Sectors

    Sectors

    View All Sectors
  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - Newron Pharmaceuticals

Healthcare

Sparks - Newron Pharmaceuticals

More on this equity
Newron Pharmaceuticals (SIX: NWRN) H126 results: Key readouts remain on track
Published by Arron Aatkar, PhD

Newron’s H126 update confirms that the pivotal evenamide programme remains on track: ENIGMA-TRS 1 has completed screening, with enrolment of at least 600 patients expected around mid-October and 12-week top-line data expected in Q127. For ENIGMA-TRS 2, enrolment continues outside the US and, following the constructive Type A meeting with the FDA in July, management remains confident that US centres will resume enrolling in the near future once the discussed changes are implemented. H126 revenue was €3.2m (H125: €11.9m), while R&D spend increased to €14.6m (€6.1m) as Phase III activity accelerated, resulting in a €16.4m net loss. Cash and current financial assets stood at €32.9m at end-June 2026, with a further c €11m added post period from the financing tranche and EA Pharma milestone; importantly, management expects available cash resources to fund operations through most of 2027 and therefore beyond the 12-week readouts from both ENIGMA-TRS studies.

Next Sparks Commentary in this sector >

Latest

Consumer | Comment

Alter Ego Media (ATHENS: AEM) – Strong H126 results

Industrials | Comment

VinFast (NASDAQ: VFS) expands US dealership network as part of next growth phase

Healthcare | Comment

SynAct Pharma (STO:SYNACT) gains WHO dengue validation for resomelagon

Healthcare | Comment

Mendus (OMX: IMMU) – DIVA opens a new AML front

Consumer | Comment

Games Workshop Group (LSE:GAW) Q127 trading update and dividend
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.